Research ArticleClinical Investigation
A Clinical Trial of Radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for Non-Hodgkin's Lymphoma
Robert T. O'Donnell, Gerald L. DeNardo, David L. Kukis, Kathleen R. Lamborn, Sui Shen, Aina Yuan, Desiree S. Goldstein, Catherine E. Carr, Gary R. Mirick and Sally J. DeNardo
Journal of Nuclear Medicine December 1999, 40 (12) 2014-2020;
Robert T. O'Donnell
Gerald L. DeNardo
David L. Kukis
Kathleen R. Lamborn
Sui Shen
Aina Yuan
Desiree S. Goldstein
Catherine E. Carr
Gary R. Mirick


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
A Clinical Trial of Radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for Non-Hodgkin's Lymphoma
Robert T. O'Donnell, Gerald L. DeNardo, David L. Kukis, Kathleen R. Lamborn, Sui Shen, Aina Yuan, Desiree S. Goldstein, Catherine E. Carr, Gary R. Mirick, Sally J. DeNardo
Journal of Nuclear Medicine Dec 1999, 40 (12) 2014-2020;
A Clinical Trial of Radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for Non-Hodgkin's Lymphoma
Robert T. O'Donnell, Gerald L. DeNardo, David L. Kukis, Kathleen R. Lamborn, Sui Shen, Aina Yuan, Desiree S. Goldstein, Catherine E. Carr, Gary R. Mirick, Sally J. DeNardo
Journal of Nuclear Medicine Dec 1999, 40 (12) 2014-2020;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
- Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising {alpha}-Particle, {beta}--Particle, and Auger Electron Emitters
- Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice
- Radioimmunotherapy of non-Hodgkin lymphomas
- Therapeutic Advantage of 90Yttrium- versus131Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer